Efficacy and safety of daratumumab versus bortezomib in the treatment of multiple myeloma
Objective To compare the efficacy and safety of daratumumab and bortezomib in the treatment of multiple myeloma(MM).Methods A total of 78 MM patients admitted to Nanchong Central Hospital from January 2022 to May 2023 were selected and divided into the study group and the control group with 39 cases respectively according to random number table method.The study group was treated with daratumumab combined with lenalidomide and dexamethasone,while the control group was treated with bortezomib combined with lenalidomide and dexamethasone.The efficacy,progression-free survival(PFS),renal function index(β2-MG,SCr,BUN)levels and quality of life score before and after treatment,as while as adverse reactions were compared between the two groups.Results The total remission rate of the study group was higher than that of the control group(x2=4.768,P=0.029),and the PFS was longer than that of the control group(P＜0.01).After treatment,the levels of β2-MG,SCr and BUN in two groups were lower than before treatment,and those in study group were lower than those in control group(P＜0.01).Symptom management,daily activity ability and emotional state scores in two groups were higher than before treatment,and those in the study group were higher than those in the control group(P＜0.01).The overall incidence of adverse reactions in the study group was lower than that in the control group(15.38％vs.38.46％,x2=5.278,P=0.022).Conclusion Daratumumab combined therapy is effective in improving the total remission rate,prolonging PFS,protecting patients'kidney function and improving quality of life in MM patients,and has fewer adverse reactions and high safety.
万方数据
维普
